外泌体在前列腺癌中的应用

doi:10.3760/cma.j.cn371439-20200401-00093

摘要/Abstract

摘要：

前列腺癌细胞来源的外泌体可直接或间接促进前列腺癌细胞的生长、转移,其可作为前列腺癌诊断及预后评估的标志物,并参与前列腺癌的临床治疗,如靶向治疗、耐药性评估、肿瘤疫苗制备等。随着各项研究的开展及技术进步,外泌体将在前列腺癌的诊治中发挥巨大作用。

关键词: 前列腺肿瘤, 外泌体

Abstract:

Exosomes derived from prostate cancer cells can directly or indirectly promote the growth and metastasis of prostate cancer cells. It was found that it can be used as a marker for diagnosis and prognosis evaluation of prostate cancer, and participate in the clinical treatment of prostate cancer, such as targeted therapy, drug resistance assessment, tumor vaccine preparation, etc. With the development of various studies and technological progress, exosomes will play a huge role in the diagnosis and treatment of prostate cancer.

Key words: Prostatic neoplasms, Exosomes

张佳伟, 吴建臣. 外泌体在前列腺癌中的应用[J]. 国际肿瘤学杂志, 2020, 47(10): 634-636.

Zhang Jiawei, Wu Jianchen. Application of exosomes in prostates cancer[J]. Journal of International Oncology, 2020, 47(10): 634-636.

参考文献 27

[1]	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019,41(1):19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005.
[2]	DeSantis CE, Miller KD, Goding Sauer A, et al. Cancer statistics for African Americans, 2019[J]. CA Cancer J Clin, 2019,69(3):211-233. DOI: 10.3322/caac.21555. doi: 10.3322/caac.21555 pmid: 30762872
[3]	Kalra H, Drummen GP, Mathivanan S. Focus on extracellular vesicles: introducing the next small big thing[J]. Int J Mol Sci, 2016,17(2):170. DOI: 10.3390/ijms17020170. doi: 10.3390/ijms17020170 pmid: 26861301
[4]	Shiao SL, Chu GC, Chung LW. Regulation of prostate cancer progression by the tumor microenvironment[J]. Cancer Lett, 2016,380(1):340-348. DOI: 10.1016/j.canlet.2015.12.022. doi: 10.1016/j.canlet.2015.12.022 pmid: 26828013
[5]	Hosseini-Beheshti E, Choi W, Weiswald LB, et al. Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment[J]. Oncotarget, 2016,7(12):14639-14658. DOI: 10.18632/oncotarget.7052. doi: 10.18632/oncotarget.7052 pmid: 26840259
[6]	Paggetti J, Haderk F, Seiffert M, et al. Exosomes released by chronic lymphocytic leukemia cells induce the transition ofstromal cells into cancer-associated fibroblasts[J]. Blood, 2015,126(9):1106-1117. DOI: 10.1182/blood-2014-12-618025. doi: 10.1182/blood-2014-12-618025 pmid: 26100252
[7]	Karlsson T, Lundholm M, Widmark A, et al. Tumor cell-derived exosomes from theprostate cancer cell line tramp-c1 impair osteoclast formation and differentiation[J]. PLoS One, 2016,11(11):e0166284. DOI: 10.1371/journal.pone.0166284. doi: 10.1371/journal.pone.0166284 pmid: 27832183
[8]	Benites BD, Alvarez MC, Saad STO. Small particles, big effects: the interplay between exosomes and dendritic cells in antitumor immunity and immunotherapy[J]. Cells, 2019, 8(12). pii: E1648. DOI: 10.3390/cells8121648. doi: 10.3390/cells8121640 pmid: 31847428
[9]	Shushkova NA, Novikova SE, Zgoda VG. Exosomes of malignant tumors: prospects of omics diagnostics[J]. Biomed Khim, 2019,65(6):457-467. DOI: 10.18097/PBMC20196506457. doi: 10.18097/PBMC20196506457 pmid: 31876516
[10]	Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer[J]. Br J Cancer, 2012,106(4):768-774. DOI: 10.1038/bjc.2011.595. doi: 10.1038/bjc.2011.595 pmid: 22240788
[11]	Li Z, Ma YY, Wang J, et al. Exosomal microRNA-141 is upregu-lated in the serum of prostate cancer patients[J]. Onco Targets Ther, 2015,9:139-148. DOI: 10.2147/OTT.S95565. doi: 10.2147/OTT.S95565 pmid: 26770063
[12]	De Palma G, Di Lorenzo VF, Krol S, et al. Urinary exosomal shuttle RNA: promising cancer diagnosis biomarkers of lower urinary tract[J]. Int J Biol Markers, 2019,34(2):101-107. DOI: 10.1177/1724600819827023. doi: 10.1177/1724600819827023 pmid: 30862241
[13]	Rodríguez M, Bajo-Santos C, Hessvik NP, et al. Identification of non-invasive mirnas biomarkers for prostate cancer by deepsequen-cing analysis of urinary exosomes[J]. Mol Cancer, 2017,16(1):156. DOI: 10.1186/s12943-017-0726-4. doi: 10.1186/s12943-017-0726-4 pmid: 28982366
[14]	Hosseini-Beheshti E, Pham S, Adomat H, et al. Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes[J]. Mol Cell Proteomics, 2012,11(10):863-885. DOI: 10.1074/mcp.M111.014845. doi: 10.1074/mcp.M111.014845
[15]	Wang L, Skotland T, Berge V, et al. Exosomal proteins as prostate cancer biomarkers in urine: from mass spectrometry discovery to immunoassay-based validation[J]. Eur J Pharm Sci, 2017,98:80-85. DOI: 10.1016/j.ejps.2016.09.023. doi: 10.1016/j.ejps.2016.09.023 pmid: 27664330
[16]	Endzeliņš E, Berger A, Melne V, et al. Detection of circulating mirnas: comparative analysis of extracellular vesicle-incorporated mirnas and cell-free mirnas in whole plasma of prostate cancer patients[J]. BMC Cancer, 2017,17(1):730. DOI: 10.1186/s12885-017-3737-z. doi: 10.1186/s12885-017-3737-z pmid: 29121858
[17]	Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer[J]. Eur Urol, 2015,67(1):33-41. DOI: 10.1016/j.eururo.2014.07.035. doi: 10.1016/j.eururo.2014.07.035 pmid: 25129854
[18]	Wani S, Kaul D, Mavuduru RS, et al. Urinary-exosomal mir-2909: a novel pathognomonic trait of prostate cancer severity[J]. J Biote-chnol, 2017,259:135-139. DOI: 10.1016/j.jbiotec.2017.07.029.
[19]	Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumorselective drug delivery, low therapeutic efficacy and unsustainable costs[J]. Clin Transl Med, 2018,7(1):11. DOI: 10.1186/s40169-018-0185-6. doi: 10.1186/s40169-018-0185-6 pmid: 29541939
[20]	H Rashed M, Bayraktar E, K Helal G, et al. Exosomes: from garbage bins to promising therapeutic targets[J]. Int J Mol Sci, 2017, 18(3). pii: E538. DOI: 10.3390/ijms18030538. pmid: 28335433
[21]	Saari H, Lázaro-Ibáezñ E, Viitala T, et al. Microvesicle-and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells[J]. J Control Release, 2015,220(Pt B):727-737. DOI: 10.1016/j.jconrel.2015.09.031. doi: 10.1016/j.jconrel.2015.09.031 pmid: 26390807
[22]	Oskouie MN, Aghili Moqhaddam NS, Butler AE, et al. Therapeutic use of curcumin-encapsulated and curcumin-primed exosomes[J]. J Cell Physiol, 2019,234(6):8182-8191. DOI: 10.1002/jcp.27615. doi: 10.1002/jcp.27615 pmid: 30317632
[23]	Yim N, Ryu SW, Choi K, et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module[J]. Nat Commun, 2016,7:12277. DOI: 10.1038/ncomms12277. doi: 10.1038/ncomms12277 pmid: 27447450
[24]	Morishita M, Takahashi Y, Matsumoto A, et al. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cellderived exosomes with immunostimulatory CpG DNA[J]. Biomaterials, 2016,111:55-65. DOI: 10.1016/j.biomaterials.2016.09.031. doi: 10.1016/j.biomaterials.2016.09.031 pmid: 27723556
[25]	Kato T, Mizutani K, Kameyama K, et al. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer[J]. Urol Oncol, 2015, 33(9): 385, e15-e20. DOI: 10.1016/j.urolonc.2015.04.019. doi: 10.1016/j.urolonc.2015.04.019
[26]	Li J, Yang X, Guan H, et al. Exosome-derived microRNAs contri-bute to prostate cancer chemoresistance[J]. Int J Oncol, 2016,49(2):838-846. DOI: 10.3892/ijo.2016.3560. doi: 10.3892/ijo.2016.3560 pmid: 27278879
[27]	Boukovala M, Spetsieris N, Weldon JA, et al. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer[J]. Eur J Cancer, 2020,127:67-75. DOI: 10.1016/j.ejca.2019.12.027. doi: 10.1016/j.ejca.2019.12.027 pmid: 31986451